Welcome to our dedicated page for OKYO PHARMA news (Ticker: OKYO), a resource for investors and traders seeking the latest updates and insights on OKYO PHARMA stock.
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical-stage, ophthalmology-focused biopharmaceutical company developing novel therapies for neuropathic corneal pain (NCP), dry eye disease, and other ocular inflammatory conditions. Its news flow centers on the progress of its lead investigational drug candidate, urcosimod, and related clinical, regulatory, and corporate developments.
Visitors to this news page can review company-issued announcements about Phase 2 clinical trial results, including data showing reductions in neuropathic corneal pain and exploratory findings on corneal nerve structure in NCP patients treated with urcosimod. OKYO also reports on earlier Phase 2 results in dry eye disease, where urcosimod demonstrated statistically significant outcomes on multiple endpoints in a 240-patient trial.
In addition to clinical data, OKYO’s news releases cover planned development milestones such as the registration pathway and a proposed multiple-ascending-dose, multi-center trial in approximately 100 NCP patients, as well as references to urcosimod’s Fast-Track designation and anticipated regulatory interactions. Corporate communications include participation in ophthalmology and life science conferences, such as the Ophthalmology Innovation Summit and BIO-Europe, where management presents updates on urcosimod and the company’s pipeline.
Investors can also find announcements related to share acquisitions by Panetta Partners Limited, an entity with a beneficial interest held by OKYO’s Executive Chairman, as disclosed in both news releases and accompanying Form 6-K filings. Together, these updates provide a view into how OKYO is advancing urcosimod as a potential first-in-class therapy for neuropathic corneal pain and dry eye disease, and how it communicates key milestones to the market.
OKYO Pharma (Nasdaq: OKYO) announced acceptance of a Phase 2 urcosimod abstract for presentation at the 2026 ASCRS Annual Meeting on April 11, 2026 in Washington, DC. The abstract reports efficacy and safety results from a proof-of-concept pilot Phase 2 study, including pain reduction and corneal nerve health trends.
The company notes urcosimod previously received the first IND to treat NCP and FDA fast track designation, and expects to initiate a 150-patient Phase 2b/3 multiple-dose study in the first half of 2026.
OKYO Pharma (Nasdaq: OKYO) announced a successful Type C meeting with the FDA on Jan 28, 2026, confirming the proposed Phase 2b/3 design for urcosimod to treat neuropathic corneal pain. The FDA agreed the primary endpoint (VAS pain reduction at Week 12; ≥2-point improvement meaningful), endorsed sample size and powering, supported OPAS as supportive QoL evidence, and aligned on CMC and key clinical elements. OKYO expects to initiate a 120-patient Phase 2b/3 multiple-dose study in the first half of 2026.
OKYO Pharma (Nasdaq: OKYO) announced the FDA authorized a single-patient expanded access Investigational New Drug (IND 176297) application for urcosimod 0.05% to treat a patient with severe neuropathic corneal pain (NCP).
The company said it will provide urcosimod under the physician-sponsored compassionate use IND and noted urcosimod previously received FDA fast track designation. OKYO expects to initiate a 120-patient Phase 2b/3 multiple-dose study of urcosimod for NCP in 2026.
OKYO Pharma (NASDAQ: OKYO) appointed industry veteran Robert J. Dempsey as Chief Executive Officer effective January 5, 2026, with Gary S. Jacob, Ph.D., transitioning to Chief Development Officer and remaining on the Board.
Dempsey brings 20+ years of global ophthalmology experience, led commercialization of Xiidra (sale: $3.4B upfront, up to $1.9B milestones), and oversaw Restasis commercial activities. The Board unanimously approved the leadership change aimed at advancing lead asset urcosimod for neuropathic corneal pain and inflammatory eye disorders.
OKYO Pharma (NASDAQ: OKYO) rang the Opening Bell at Nasdaq MarketSite in Times Square on December 19, 2025 from 9:15 AM to 9:45 AM ET.
The ceremony featured Executive Chairman and Founder Gabriele Cerrone and the management team and celebrated progress on OKYO's clinical pipeline, highlighted by lead candidate urcosimod, a lipid-conjugated chemerin peptide agonist targeting ChemR23 for neuropathic corneal pain (NCP).
The company noted positive Phase 2 results for urcosimod showing favourable corneal nerve outcomes and pain reduction; the bell-ringing was livestreamed on Nasdaq channels.
OKYO Pharma (NASDAQ: OKYO) announced on Dec 15, 2025 that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 24,551 ordinary shares on NASDAQ.
After the purchase, the Chairman's total holding increased to 10,516,297 shares. OKYO is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition currently without an FDA-approved therapy.
OKYO Pharma (NASDAQ: OKYO) reported new analyses from its placebo-controlled, randomized, double-masked Phase 2 trial of 0.05% urcosimod in neuropathic corneal pain (NCP) on Dec 11, 2025. The 18-patient trial's exploratory corneal nerve imaging (in vivo confocal microscopy) showed median increases for 0.05% patients in total nerve fiber count (+2.0 n/0.16 mm², IQR 0.54–3.63) and total nerve fiber length (+2.6 mm/mm², IQR 1.55–5.67; p = 0.057 vs placebo).
The placebo group showed median decreases in nerve count (–1.92 n/0.16 mm², IQR –2.79 to –0.04) and length (–1.63 mm/mm², IQR –3.76 to 0.63). Results are described as exploratory (n = 4 per reported median) and presented as directionally favorable for corneal nerve structure, supporting further investigation.
OKYO Pharma (NASDAQ: OKYO) announced that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 27,051 ordinary shares on NASDAQ on Dec 3, 2025.
The purchase increases the Chairman's total holding to 10,491,746 shares. The company is developing urcosimod for neuropathic corneal pain, a condition with no FDA-approved therapy.
OKYO Pharma (NASDAQ: OKYO) announced that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 82,018 ordinary shares on NASDAQ on November 21, 2025.
The purchase increases the Chairman's total holding to 10,464,695 shares. The company is developing urcosimod for neuropathic corneal pain (NCP), an ocular condition without an FDA-approved therapy.
OKYO Pharma (NASDAQ: OKYO) announced that CEO Gary S. Jacob, Ph.D. will present at OIS XV in San Diego on November 22, 2025 from 8:30–9:30 AM PT during the Anterior Innovation Showcase. The presentation will highlight OKYO's lead investigational drug urcosimod, a lipidated peptide for neuropathic corneal pain (NCP).
OKYO said recent positive top-line Phase 2 results support advancing to a 120-patient multi-center clinical trial, and the OIS XV session aims to engage clinicians, partners, and investors to accelerate development.
FAQ
What is the current stock price of OKYO PHARMA (OKYO)?
What is the market cap of OKYO PHARMA (OKYO)?
